Please login to view this media
- Talk
- 15/09/2021
- Canada
Flap Reconstruction Decreases Complication Rates following Resection of Adductor Compartment Soft Tissue Sarcoma
Description
In this presentation delivered by Rostislav Novak, a fellow in MSK oncology at Mount Sinai Hospital, the focus is on soft tissue sarcoma—a type of malignancy arising from mesenchymal tissues, primarily affecting the extremities, particularly the medial thigh. The treatment challenges are highlighted, especially concerning surgeries involving adductor compartment tumors, where complications often exceed 50% due to large tumor size and the effects of local control following resection.
The speaker discusses two primary methods of managing postoperative resection areas: primary closure and flap reconstruction, detailing a retrospective study comparing the outcomes of patients treated with each method. Although no significant differences were found in postoperative complication rates between the two groups, it was noted that the hospital stay was notably longer for patients undergoing flap reconstruction compared to those with primary closure.
The study further investigates the impact of tumor size on postoperative outcomes, revealing that a tumor diameter exceeding 15 centimeters correlates with decreased outcomes in primary closure methods. For volumes above 800 milliliters, flap reconstruction demonstrates advantage, suggesting this method is more beneficial in larger tumor cases. Curves representing probabilities of uncomplicated wound healing indicate that for tumors beyond 336 milliliters, flap reconstruction leads to better outcomes. The findings suggest that using flap reconstruction should be based on tumor volume, with less benefit observed for volumes below 336 milliliters and stronger justification for their use above 600 milliliters.
Overall, the presentation emphasizes the need for strategic decision-making in surgical approaches encompassing various factors such as patient age and potential complications, ultimately providing clarity in the treatment of soft tissue sarcomas.